Health & Wellness Company Announces Development of Weight Management Drug

Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, and hormone replacement therapies, is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share. The GLP-1 receptor agonists’ market, encompassing both Semaglutide and Tirzepatide, is projected to reach over $164 billion in combined revenue by 2032, according to Visible Alpha consensus. This represents a significant increase from $37.9 billion in 2023. These are record-breaking revenues for any drug class in the history of drug development, underscoring the immense potential and growing demand for these medications. $Mangoceuticals(MGRX.US)$